|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EB01
|
|
gptkbp:brand
|
gptkb:Iressa
|
|
gptkbp:CASNumber
|
184475-35-2
|
|
gptkbp:chemicalFormula
|
quinazoline derivative
|
|
gptkbp:contraindication
|
hypersensitivity to gefitinib
|
|
gptkbp:drugClass
|
antineoplastic agent
|
|
gptkbp:eliminationHalfLife
|
41 hours
|
|
gptkbp:genericName
|
gptkb:gefitinib
|
|
gptkbp:hasMolecularFormula
|
C22H24ClFN4O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Iressa
|
|
gptkbp:indication
|
gptkb:EGFR_mutation-positive_NSCLC
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
|
gptkbp:mechanismOfAction
|
gptkb:EGFR_tyrosine_kinase_inhibitor
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
D (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
anorexia
rash
interstitial lung disease
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:gefitinib
gptkb:Gefitinib
|
|
gptkbp:bfsLayer
|
7
|